This research is Trending!
Influence of Disease-Modifying Therapy on the Efficacy of Vutrisiran in Transthyretin Cardiac Amyloidosis
Key result
Vutrisiran maintains mortality and CV event benefits regardless of concurrent tafamidis or HF therapies.
- n=654
Why the study?
Whether concomitant disease-modifying or heart failure therapy modifies the efficacy of vutrisiran in patients with transthyretin amyloid cardiomyopathy has not been described.
Does vutrisiran reduce all-cause mortality and recurrent cardiovascular events in patients with transthyretin amyloid cardiomyopathy regardless of concomitant disease-modifying or heart failure therapy?
Population
654 randomized patients with transthyretin amyloid cardiomyopathy
Comparison
Vutrisiran vs placebo
Design
Randomized controlled trial
Authors
Discussion
Loading...
Member takes
Overview
Vutrisiran benefit holds irrespective of tafamidis or background HF therapy; extends RCT evidence to contemporary ATTR-CM polypharmacy.
Key Points
- To assess patterns of concomitant therapy use in the HELIOS-B trial and determine whether background disease-modifying or heart failure medications modify the therapeutic efficacy of vutrisiran in transthyretin amyloid cardiomyopathy.
- Secondary analysis of the randomized HELIOS-B trial (NCT04153149) in 654 patients with transthyretin amyloid cardiomyopathy assigned to vutrisiran or placebo.
- Tracked baseline use and post-randomization initiation of tafamidis, SGLT2 inhibitors, mineralocorticoid receptor antagonists, beta-blockers, and renin-angiotensin system inhibitors.
- Used time-updated Lin-Wei-Yang-Ying models to evaluate treatment effect modification on the primary composite endpoint of all-cause mortality and recurrent cardiovascular events.
- At baseline, 40% of patients received tafamidis and 77% received at least one heart failure medication, with heart failure drug initiation rates during follow-up being numerically higher in the placebo arm.
- No statistically significant treatment effect modification was observed across baseline or time-updated medication classes for the primary composite endpoint (P-interaction: tafamidis 0.95, SGLT2 inhibitors 0.59, mineralocorticoid receptor antagonists 0.92, beta-blockers 0.75, renin-angiotensin system inhibitors 0.82).
Study Design
Type
RCT (n=654)
Randomization
Randomized
Structured PICO
Does vutrisiran reduce all-cause mortality and recurrent cardiovascular events in patients with transthyretin amyloid cardiomyopathy regardless of concomitant disease-modifying or heart failure therapy?
P
Population
654 patients with transthyretin amyloid cardiomyopathy (40% on baseline tafamidis, 77% on heart failure medication) randomized to vutrisiran or placebo.
I
Intervention
Vutrisiran
C
Comparator
Placebo
O
Outcome
Composite endpoint of all-cause mortality and recurrent cardiovascular eventscomposite
The efficacy of vutrisiran in reducing mortality and cardiovascular events in ATTR-CM is consistent regardless of concomitant use of tafamidis or standard heart failure therapies.
Coverage & sources
Journal, society, and media accounts. Useful signal, not independent expert judgment.
Cite This Study
Abovich et al. (2026) conducted an RCT in Transthyretin amyloid cardiomyopathy (ATTR-CM) (n=654). Vutrisiran vs. Placebo was evaluated on Composite endpoint of all-cause mortality and recurrent cardiovascular events. The treatment benefit of vutrisiran on mortality and recurrent cardiovascular events was not modified by concomitant use of tafamidis (P-interaction=0.95) or heart failure therapies.